Eating Disorders
Overview of Eating Disorders
Eating disorders are serious psychiatric disorders characterized by abnormal eating or weight-control behaviors. Disturbing attitudes towards weight, body shape, and eating play a key role in their origin and maintenance. The form of these concerns varies by gender; in men, for example, body image concerns might focus on muscularity, whereas in women, these concerns might focus more on weight loss. Obesity per se is not framed as an eating disorder. All eating disorders considerably impair physical health and disrupt psychosocial functioning. Both the diagnostic and statistical manual (DSM-5) and the international classification of diseases (ICD-11) encompass six main feeding and eating disorders. These include the familiar diagnostic categories of anorexia nervosa, bulimia nervosa, and binge eating disorder. In addition, three disorders previously mainly viewed as childhood disorders have been included. These are avoidant-restrictive food intake disorder, pica, and rumination disorder. DSM-5 also provides subtype qualifiers, severity indicators, and definitions of remission.
Aetiology of Eating Disorders
Aetiology diagram of restrictive-type eating disorders
Biological factors
|
|
Psychological factors
|
|
Psychosocial factors
|
Behavioral factors
|
Aetiology diagram of bulimic spectrum eating disorders
Biological factors
|
|
Psychological factors
|
|
Psychosocial factors
|
Behavioral factors
|
Treatment of Eating Disorders
Early intervention improves outcomes; therefore, rapid commencement of specialized eating disorder treatment and care rather than watchful waiting is essential. For mild or moderately severe cases, the first step is an outpatient psychological treatment involving family members in an age-appropriate manner. If the medical or psychological risk is high or there is an irresponsiveness to outpatient care, then the greater intensity of care can be provided by outreach, day, or inpatient facilities. Studies in the UK National Health Service suggest that about 20-35% of patients will need this higher level of care. There is uncertainty about the management of patients who continue to be symptomatic following these first-line treatments, although recovery remains possible for more than 60% of patients even after 20 years. Patients often request that their families and treatment teams should not give up on them. New forms of treatments are being considered for this group, but some aspects of management are controversial. Transitions between services for age, educational, or physical reasons need to be carefully managed.
Trend of Research
Over the past 50 years and in the context of major changes in our environment, eating disorders have evolved into a variety of forms with overlapping and distinct clinical and aetiological features, affecting people of all ages and social classes. The prevalence of eating disorders is moderately high, although most affected individuals do not present for treatment. Lengthy periods of untreated symptoms can lead to an entrenched form of illness, which is more difficult to treat. In brief, advances are needed to allow more precise elucidation of the mechanisms that underpin these problems and to develop more targeted treatments. At the same time, disseminable and scalable treatments are needed.
If you are working on eating disorders and need any assistance, or you have any other questions about our services, please don’t hesitate to contact us for more information.

- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- iNeu™ Human Motor Neurons (Cat#: NCL-2103-P71)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Mouse Glioma Cell Line GL261 (Cat#: NCL-2108P28)
- Green Fluorescent Tau cell Line (Cat#: NCL2110P219)
- Rat Retinal Muller Cell Line, Immortalized (Cat#: NCL-21P6-192)
- Green Fluorescent Alpha-synuclein Cell Line (Cat#: NCL2110P209)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)